Brokerages Set Abbott Laboratories (NYSE:ABT) Target Price at $119.50

Abbott Laboratories (NYSE:ABT) has earned a consensus recommendation of “Moderate Buy” from the twenty-seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, twenty have given a buy rating and three have assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $119.50.

Several research firms have recently weighed in on ABT. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. TD Cowen reiterated a “buy” rating and issued a $135.00 price target on shares of Abbott Laboratories in a report on Tuesday. JPMorgan Chase & Co. boosted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Finally, Bank of America cut their target price on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th.

Abbott Laboratories Price Performance

ABT stock opened at $103.37 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The firm has a market cap of $178.87 billion, a P/E ratio of 33.45, a P/E/G ratio of 1.95 and a beta of 0.59. The company’s 50-day moving average price is $105.46 and its two-hundred day moving average price is $99.84.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abbott Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of ABT. Menlo Advisors LLC lifted its position in shares of Abbott Laboratories by 1.1% during the 2nd quarter. Menlo Advisors LLC now owns 67,919 shares of the healthcare product maker’s stock valued at $6,162,000 after buying an additional 723 shares during the last quarter. Core Capital Management & Research inc. bought a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $64,000. The Manufacturers Life Insurance Company lifted its stake in shares of Abbott Laboratories by 5.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,370,397 shares of the healthcare product maker’s stock valued at $487,310,000 after buying an additional 254,205 shares in the last quarter. Capstone Financial Advisors Inc. boosted its holdings in Abbott Laboratories by 10.6% in the 2nd quarter. Capstone Financial Advisors Inc. now owns 3,300 shares of the healthcare product maker’s stock worth $299,000 after buying an additional 316 shares during the period. Finally, Archford Capital Strategies LLC lifted its position in shares of Abbott Laboratories by 17.2% during the second quarter. Archford Capital Strategies LLC now owns 2,715 shares of the healthcare product maker’s stock worth $246,000 after acquiring an additional 398 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.